Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said its mRNA-based COVID-19 vaccine DS-5670 met the main goal in a booster vaccination trial. The Japanese company said the booster vaccination trial included ~5K Japanese healthy adult and elderly people who had compl...
An expert panel of the European Medicines Agency (EMA) has recommended issuing marketing authorization for Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) to include gastric cancer as an indication for Enhertu, an antibody-drug conjugate the company develops with AstraZeneca ( ...
Daiichi Sankyo Company, Limited (DSKYF) Q2 2022 Results Conference Call October 31, 2022 01:30 AM ET Company Participants Sunao Manabe - Representative Director, President and CEO Wataru Takasaki - Head, R&D Division Hiroyuki Okuzawa - Head, Corporate Plannin...
Summary Global growth stocks held up better than value, snapping a two-quarter losing streak, as global recession fears weighed more heavily on companies tied to the broader economy. The Strategy outperformed for the second quarter in a row, thanks in large part to positioning adj...
Daiichi Sankyo Co. press release ( OTCPK:DSKYF ): 1H GAAP EPS of ¥30.39. Revenue of ¥607.79B (+14.7% Y/Y). For further details see: Daiichi Sankyo Co. GAAP EPS of ¥30.39, revenue of ¥607.79B
Summary The Strategy outperformed for the second quarter in a row, thanks in large part to positioning adjustments made over the last year in preparation for these extreme macro headwinds. We enhanced a focus on sturdy, secular growth businesses with three new additions to the portfol...
Summary International growth stocks held up better than value, snapping a two-quarter losing streak, as global recession fears weighed more heavily on companies tied to the broader economy. The Strategy outperformed for the second quarter in a row, thanks in large part to position...
Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said on Sept. 26 that Ezharmia was approved in Japan to treat patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL), a rare type of blood cancer. Ezharmia (valemetostat tosilate) is the first ...
Gilead Sciences ( NASDAQ: GILD ) shares reached the highest level since February on Monday in reaction to its announcement that antibody-drug conjugate Trodelvy significantly improved overall survival in a Phase 3 trial involving certain patients with HR+/ HER2- metastatic bre...
AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo's ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) Enhertu delayed disease progression, meeting the main goal of a phase 3 trial in patients with a type of breast cancer. The study, dubbed DESTINY-Breast02, evaluated Enhertu (t...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...